AstraZeneca’s Farxiga Decreases Risk of Type 2 Diabetes Onset in Patients with Heart Failure

In May 2020, Farxiga (dapagliflozin) achieved a first-in-class FDA approval for reducing cardiovascular (CV) risk for HF-REF patients with or without type 2 diabetes (T2D). Credit: urbans via Shutterstock.